The estimated Net Worth of Sandra Milligan is at least $28.5 Tisíc dollars as of 15 November 2023. Sandra Milligan owns over 32,000 units of Gossamer Bio stock worth over $28,480 and over the last 3 years Sandra sold GOSS stock worth over $0.
Sandra has made over 1 trades of the Gossamer Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently Sandra bought 32,000 units of GOSS stock worth $25,280 on 15 November 2023.
The largest trade Sandra's ever made was buying 32,000 units of Gossamer Bio stock on 15 November 2023 worth over $25,280. On average, Sandra trades about 6,400 units every 0 days since 2021. As of 15 November 2023 Sandra still owns at least 32,000 units of Gossamer Bio stock.
You can see the complete history of Sandra Milligan stock trades at the bottom of the page.
Sandra's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.
Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain a Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio executives and other stock owners filed with the SEC include: